For instance, from a cost perspective view 68Ga PSMA PET/CT (68Ga Prostate-Specific Membrane Antigen PET/CT) seems to be superior to extended pelvic lymph node dissection in patients with prostate cancer [41], while 18F-FDG PET-CT seems to be superior to CT alone for preoperative evaluation of patients with monometastatic non-small-cell lung cancer (NSCLC) [42], as well as seeming to be cost-effective in the long term for the management of patients with locally advanced head and neck cancer. The gene discussed is FOLH1; the disease is non-small cell lung carcinoma.